Guided by the NGI-TAG's recommendations in 2019 and 2021, Nigeria's previously planned for HPV introduction in 2021 with the 2- doses of quadrivalent HPV recombinant vaccine (Gardasil-4) as the preferred vaccine candidate.

Amidst subsisting global HPV vaccine shortages, SAGE has recently provided additional evidence to the effect that a one dose regimen of the vaccine which is as good as the 2-dose regimen; considering  evidence from  updated systematic reviews.

Overall, the review showed comparable efficacy and effectiveness between single- and multidose schedules in preventing persistent infection with HPV serotypes 16 and 18, lasting  up to 10 years following vaccination.

Furthermore, Nigeria has recently received a vaccine supply commitment from MERK of 8 million doses of Gardasil4 in 2023 and an additional 11 million doses in 2024 towards introduction  in RI.

Against this backdrop, the NPHCDA requested NGI-TAG to review it previous recommendation of 2-dose schedule using available evidence to consider a 1-dose HPV vaccine schedule in 2023 using the Gardasil-4valent HPV vaccine as recommended by the NGI-TAG  previously.

  • Background paper
  • Africa
  • Nigeria
  • Human papillomavirus (HPV)